Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis

OBJECTIVE: Mavrilimumab, a human monoclonal antibody, targets granulocyte–macrophage colony‐stimulating factor receptor α. We undertook to determine the long‐term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in 2 phase IIb studies (1071 and 1107) and in 1 open‐label extension...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovský, Jiří, Godwood, Alex, Albulescu, Marius, Michaels, M. Alex, Guo, Xiang, Close, David, Weinblatt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947536/
https://www.ncbi.nlm.nih.gov/pubmed/29361199
http://dx.doi.org/10.1002/art.40420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947536/
https://www.ncbi.nlm.nih.gov/pubmed/29361199
http://dx.doi.org/10.1002/art.40420

Ejemplares similares